• LAST PRICE
    2.2750
  • TODAY'S CHANGE (%)
    Trending Up0.0050 (0.2203%)
  • Bid / Lots
    2.2700/ 5
  • Ask / Lots
    2.2800/ 6
  • Open / Previous Close
    2.2500 / 2.2700
  • Day Range
    Low 2.2500
    High 2.3100
  • 52 Week Range
    Low 1.6000
    High 4.2500
  • Volume
    113,622
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 2.27
TimeVolumePRTK
09:32 ET10392.25
09:33 ET1002.26
09:39 ET26092.28
09:42 ET6902.285
09:51 ET1002.28
09:53 ET8032.27
09:57 ET1002.275
10:04 ET11002.265
10:06 ET3002.26
10:08 ET1002.255
10:13 ET6002.265
10:18 ET2002.2699
10:20 ET5002.27
10:22 ET3002.275
10:27 ET2002.27
10:29 ET4002.265
10:40 ET1002.265
10:51 ET2002.26
10:58 ET2002.26
11:00 ET2002.26
11:02 ET1002.265
11:05 ET5002.265
11:07 ET24372.27
11:12 ET23002.26
11:18 ET3002.26
11:21 ET1002.265
11:23 ET21832.265
11:25 ET1002.265
11:30 ET5002.2685
11:38 ET36222.28
11:39 ET8942.28
11:48 ET47702.285
11:50 ET62672.29
11:52 ET36152.29
11:54 ET176072.29
11:56 ET21002.282
11:59 ET50462.2616
12:01 ET10542.26
12:06 ET1002.2695
12:08 ET1002.265
12:12 ET2002.265
12:14 ET2002.268
12:15 ET1002.265
12:19 ET172592.305
12:21 ET79792.295
12:26 ET84162.28
12:28 ET38002.275
12:35 ET1002.275
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPRTK
Paratek Pharmaceuticals Inc
126.1M
-1.3x
---
United StatesASRT
Assertio Holdings Inc
200.4M
7.6x
---
United StatesAOBI
American Oriental Bioengineering Inc
10.0
0.0x
---
United StatesSCTL
Societal CDMO Inc
116.6M
-5.8x
---
United StatesNAII
Natural Alternatives International Inc
54.8M
6.5x
+9.87%
United StatesAYTU
Aytu Biopharma Inc
10.3M
-0.3x
---
As of 2023-02-03

Company Information

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The Company's lead product, NUZYRA (omadacycline), is an oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI), caused by susceptible pathogens. Omadacycline is used in the emergency room, hospital, and community care settings. Its second product, SEYSARA (Sarecycline), is an oral therapy for the treatment of moderate to severe acne vulgaris.

Contact Information

Headquarters
75 Park Plaza, 4Th FloorBOSTON, MA, United States 02116
Phone
617-807-6600
Fax
617-275-0039

Executives

Executive Chairman of the Board
Michael Bigham
President, Chief Commercial Officer
Adam Woodrow
Chief Executive Officer, Director
Evan Loh
Chief Legal Officer, General Counsel, Company Secretary
William Haskel
Chief Development and Regulatory Officer
Randall Brenner

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$126.1M
Revenue (TTM)
$116.5M
Shares Outstanding
55.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.49
EPS
$-1.69
Book Value
$-2.47
P/E Ratio
-1.3x
Price/Sales (TTM)
1.1
Price/Cash Flow (TTM)
---
Operating Margin
-60.64%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.